Primaquine treatment and relapse in Plasmodium vivax malaria.
Rishikesh K, Saravu K.
Pathog Glob Health. 2016;110(1):1-8. doi: 10.1080/20477724.2015.1133033. Epub 2016 Feb 18.
Relapse or reinfection: Classification of malaria infection using transition likelihoods.
Lin FC, Li Q, Lin JT.
Biometrics. 2020 Dec;76(4):1351-1363. doi: 10.1111/biom.13226. Epub 2020 Mar 3.
Prevalence of malaria relapse: systematic review with meta-analysis.
Nascimento TLD, Vasconcelos SP, Peres Y, Oliveira MJS, Taminato M, Souza KMJ.
Rev Lat Am Enfermagem. 2019 Mar 18;27:e3111. doi: 10.1590/1518-8345.2619.3111.
Relapse.
White NJ, Imwong M.
Adv Parasitol. 2012;80:113-50. doi: 10.1016/B978-0-12-397900-1.00002-5.
Determinants of relapse periodicity in Plasmodium vivax malaria.
White NJ.
Malar J. 2011 Oct 11;10:297. doi: 10.1186/1475-2875-10-297.
The hypnozoite and relapse in primate malaria.
Cogswell FB.
Clin Microbiol Rev. 1992 Jan;5(1):26-35. doi: 10.1128/CMR.5.1.26.
A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria.
Groger M, Fischer HS, Veletzky L, Lalremruata A, Ramharter M.
Malar J. 2017 Mar 11;16(1):112. doi: 10.1186/s12936-017-1759-2.
Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
Wångdahl A, Sondén K, Wyss K, Stenström C, Björklund D, Zhang J, Hervius Askling H, Carlander C, Hellgren U, Färnert A.
Clin Infect Dis. 2022 Apr 9;74(7):1199-1207. doi: 10.1093/cid/ciab610.
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Watson JA, White NJ.
N Engl J Med. 2022 Jul 21;387(3):282-283. doi: 10.1056/NEJMc2205922.
Higher-Dose Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Taylor WRJ, Nguyen Pouplin J, Daher A.
N Engl J Med. 2022 Jul 21;387(3):282. doi: 10.1056/NEJMc2205922.
